JP2023529612A - 敗血症の治療のためのクロマノール、キノン又はヒドロキノン化合物 - Google Patents

敗血症の治療のためのクロマノール、キノン又はヒドロキノン化合物 Download PDF

Info

Publication number
JP2023529612A
JP2023529612A JP2022574167A JP2022574167A JP2023529612A JP 2023529612 A JP2023529612 A JP 2023529612A JP 2022574167 A JP2022574167 A JP 2022574167A JP 2022574167 A JP2022574167 A JP 2022574167A JP 2023529612 A JP2023529612 A JP 2023529612A
Authority
JP
Japan
Prior art keywords
compound
sul
formula
carbon atoms
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529612A5 (https=
Inventor
ボウマ，ヤルマル・ローランド
クレニング，グイド
ヘニング，ロベルト・ヘンク
ファン・デル・フラーフ，アドリアヌス・コルネリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sulfateq BV
Original Assignee
Sulfateq BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq BV filed Critical Sulfateq BV
Publication of JP2023529612A publication Critical patent/JP2023529612A/ja
Publication of JP2023529612A5 publication Critical patent/JP2023529612A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022574167A 2020-06-02 2021-06-02 敗血症の治療のためのクロマノール、キノン又はヒドロキノン化合物 Pending JP2023529612A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2025730A NL2025730B1 (en) 2020-06-02 2020-06-02 Compounds for treatment of sepsis
NL2025730 2020-06-02
PCT/NL2021/050351 WO2021246868A1 (en) 2020-06-02 2021-06-02 Chromanol, quinone or hydroquinone compounds for treatment of sepsis

Publications (2)

Publication Number Publication Date
JP2023529612A true JP2023529612A (ja) 2023-07-11
JP2023529612A5 JP2023529612A5 (https=) 2024-05-27

Family

ID=72659292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574167A Pending JP2023529612A (ja) 2020-06-02 2021-06-02 敗血症の治療のためのクロマノール、キノン又はヒドロキノン化合物

Country Status (7)

Country Link
US (1) US20230202997A1 (https=)
EP (1) EP4157261A1 (https=)
JP (1) JP2023529612A (https=)
AU (1) AU2021284148A1 (https=)
CA (1) CA3185054A1 (https=)
NL (1) NL2025730B1 (https=)
WO (1) WO2021246868A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231894B1 (en) * 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
US20040097433A1 (en) * 2002-11-15 2004-05-20 Sekhar Boddupalli Chroman derivatives for the reduction of inflammation symptoms
WO2014011047A1 (en) * 2012-07-12 2014-01-16 Khondrion B.V. Chromanyl derivatives for treating mitochondrial disease
WO2014098586A1 (en) * 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells
WO2019101826A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388654B (es) * 2015-05-22 2025-03-20 Sulfateq Bv Derivados de cromano y uso de los mismos en el tratamiento de daño en un órgano diabético, tal como un riñón.
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
AU2017281744B2 (en) 2016-06-24 2022-10-27 Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón Cilastatin for use in the treatment of sepsis
FI3762018T3 (fi) 2018-03-08 2024-04-22 Am Pharma Bv Rekombinantti alkalinen fosfataasi käytettäväksi sepsikseen liittyvän akuutin munuaisvaurion hoitamiseen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231894B1 (en) * 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
US20040097433A1 (en) * 2002-11-15 2004-05-20 Sekhar Boddupalli Chroman derivatives for the reduction of inflammation symptoms
WO2014011047A1 (en) * 2012-07-12 2014-01-16 Khondrion B.V. Chromanyl derivatives for treating mitochondrial disease
WO2014098586A1 (en) * 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells
WO2019101826A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISOBE, Y., ET AL.: "Synthesis and Activity of a Metabolite of (S)-6-Amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carb", CHEM. PHARM. BULL., vol. 50, no. 10, JPN6025028466, 2002, pages 1418 - 1420, ISSN: 0005641655 *

Also Published As

Publication number Publication date
NL2025730B1 (en) 2022-01-20
EP4157261A1 (en) 2023-04-05
US20230202997A1 (en) 2023-06-29
WO2021246868A1 (en) 2021-12-09
CA3185054A1 (en) 2021-12-09
AU2021284148A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
US12458622B2 (en) Methods of treatment of coronavirus-induced inflammation conditions
US20230364044A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
EP2696864A1 (en) Therapeutic compounds
KR101899613B1 (ko) 염증 및 혈관 증식 관련 안 질환의 치료 방법
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
US20190046530A1 (en) Phase 2 inducers and related signaling pathways protect cartilage against inflammation, apoptosis and stress
JP2018526440A (ja) 免疫系を刺激するためのインドール化合物の使用
JP2023529612A (ja) 敗血症の治療のためのクロマノール、キノン又はヒドロキノン化合物
JP2016525564A (ja) 親油性スタチンと組合せ使用したメトトレキサートの効果向上
KR100386349B1 (ko) 뮤신의 분비를 저해하기 위한 알파-레틴산 수용체 길항제의 용도
US20200323793A1 (en) Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
Wong et al. The effects of N-acetylcysteine on lung alveolar epithelial cells infected with respiratory syncytial virus
WO2009019473A1 (en) Treatments for inflammatory arthritis
JP2013510838A (ja) 微生物感染症の治療
EP4346789A1 (en) Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
JP2023516539A (ja) ヒドロキシ尿素を含む炎症反応を阻害するための医薬組成物
US20250177384A1 (en) Chromanol compounds for treatment or prophylaxis of ageing-associated disorders
JPWO2020004404A1 (ja) ＩＬ−１β阻害薬
HK40115454A (zh) 用於治疗或预防衰老相关病症的苯并二氢吡喃醇化合物
US10485805B2 (en) Finafloxacin for use in the treatment of urinary tract infections
JP2019182845A (ja) キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
CN117442738A (zh) 一种联合用药物组合物在制备预防或治疗t细胞淋巴瘤的药物中的应用
HK40099294A (zh) 治疗特发性肺纤维化的辣椒素衍生物
Abraganly et al. Quinacrine rev&d

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114